KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Receivables data on record, last reported at $148.2 million in Q4 2025.

  • For Q4 2025, Receivables rose 41.58% year-over-year to $148.2 million; the TTM value through Dec 2025 reached $148.2 million, up 41.58%, while the annual FY2025 figure was $148.2 million, 41.58% up from the prior year.
  • Receivables reached $148.2 million in Q4 2025 per ACAD's latest filing, up from $139.4 million in the prior quarter.
  • Across five years, Receivables topped out at $148.2 million in Q4 2025 and bottomed at $51.8 million in Q2 2021.
  • Average Receivables over 5 years is $89.3 million, with a median of $89.3 million recorded in 2023.
  • Peak YoY movement for Receivables: dropped 8.97% in 2022, then soared 68.4% in 2023.
  • A 5-year view of Receivables shows it stood at $65.3 million in 2021, then decreased by 3.46% to $63.1 million in 2022, then skyrocketed by 62.25% to $102.4 million in 2023, then increased by 2.29% to $104.7 million in 2024, then surged by 41.58% to $148.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $148.2 million in Q4 2025, $139.4 million in Q3 2025, and $119.7 million in Q2 2025.